NCT05905341

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

This decision was based on business considerations and not due to specific safety reasons or a request from a regulatory authority.